amrinone
amrinone
CAS: 60719-84-8
Molecular Formula: C10H9N3O
amrinone - Names and Identifiers
| Name | amrinone |
| Synonyms | Inocor inocor Vesistol AMRINONE Win40680 Wincavam Wincoram amrinone Amrinona win40680 Amrinonum WIN 40680 awd08-250 AWD 08-250 cordemcura CCRIS 3794 INAMRINONE Inamrinone Cordemcura BRN 0744819 UNII-JUT23379TN Amrinonum [INN-Latin] Amrinona [INN-Spanish] 5-amino-3,4'-bipyridin-6(1H)-one 5-Amino(3,4'-bipyridin)-6(1H)-one 5-AMINO-[3,4'-BIPYRIDIN]-6[1H]-ONE 5-Amino-(3,4'-bipyridin)-6(1H)-one (3,4'-Bipyridin)-6(1H)-one, 5-amino- 3-Amino-5-(4-pyridinyl)-2(1H)-pyridinone 3-AMINO-5-(4-PYRIDINYL)-2(1H)-PYRIDINONE 5-25-15-00181 (Beilstein Handbook Reference) |
| CAS | 60719-84-8 |
| EINECS | 262-390-0 |
| InChI | InChI=1/C10H9N3O/c11-9-5-8(6-13-10(9)14)7-1-3-12-4-2-7/h1-6H,11H2,(H,13,14) |
amrinone - Physico-chemical Properties
| Molecular Formula | C10H9N3O |
| Molar Mass | 187.2 |
| Density | 1.2025 (rough estimate) |
| Melting Point | 294-297°C (dec.) |
| Boling Point | 321.94°C (rough estimate) |
| Flash Point | 226.9°C |
| Water Solubility | Insoluble in water or chloroform. Slightly soluble in acetic acid or DMF. Soluble in DMSO |
| Solubility | Soluble in water |
| Vapor Presure | 2.42E-08mmHg at 25°C |
| Appearance | Yellow needle crystal |
| Color | Crystals from DMF |
| pKa | 12.05±0.10(Predicted) |
| Storage Condition | Keep in dark place,Sealed in dry,2-8°C |
| Refractive Index | 1.4830 (estimate) |
| MDL | MFCD00083228 |
| Use | Cardiac drugs, with enhanced myocardial contractility and direct dilation of blood vessels |
| In vitro study | Amrinone (Inamrinone) produced a dose-dependent inhibition of ADP-induced rat platelet aggregation in vitro as well as ex vivo in rats. The proliferation of human aortic smooth muscle cells in culture stimulated with FBS or PDGF was also inhibited by amrinone. |
| In vivo study | Amrinone (Inamrinone) is administered subcutaneously to rats at a dose of 10 mg/kg/day for 14 days, significant reduction of neointimal thickness was noted. |
amrinone - Risk and Safety
| Risk Codes | R25 - Toxic if swallowed R36/37/38 - Irritating to eyes, respiratory system and skin. R20/21/22 - Harmful by inhalation, in contact with skin and if swallowed. |
| Safety Description | S28 - After contact with skin, wash immediately with plenty of soap-suds. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) S36 - Wear suitable protective clothing. S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. |
| UN IDs | UN 2811 6.1/PG 3 |
| WGK Germany | 3 |
| RTECS | DW2500000 |
| HS Code | 29333999 |
| Hazard Class | 6.1(b) |
| Packing Group | III |
| Toxicity | LD50 orl-rat: 102 mg/kg NDADD8 1,259,83 |
amrinone - Standard
Authoritative Data Verified Data
This product is 5-amino- (3, 4-bipyridine)-6 (lH) -one. The content of C10H9N30 shall not be less than 98.5% calculated as dried product.
Last Update：2024-01-02 23:10:35
amrinone - Trait
Authoritative Data Verified Data
- This product is light yellow to light yellow brown needle-like crystal or crystalline powder; Odorless; Light color gradient deep.
- This product is slightly soluble in methanol, very slightly soluble in ethanol, almost insoluble in water; Dissolved in lactic acid.
Last Update：2022-01-01 15:36:46
amrinone - Introduction
Colorless, tasteless, dark in light color.
Last Update：2022-10-16 17:27:00
amrinone - Differential diagnosis
Authoritative Data Verified Data
- take about 5mg of this product, add 5ml of 0.lmol/L hydrochloric acid solution, add 1ml of trinitrophenol test solution, and yellow precipitate will occur.
- take this product, add 0.1 mol /L hydrochloric acid solution is prepared to contain about 5ug per 1 ml of solution, according to UV-visible spectrophotometry (General 0401), there is maximum absorption at the wavelength of 317nm.
- The infrared absorption spectrum of this product should be consistent with that of the control (Spectrum set 809).
Last Update：2022-01-01 15:36:47
amrinone - Exam
Authoritative Data Verified Data
Related substances
take this product 25mg, precision weighing, 50ml flask, add 0.1 mol/L hydrochloric acid solution (2ml), dissolved by ultrasound, cooled, diluted to the scale with mobile phase, shaken well, used as a test solution; Take 1ml of precision measurement, put it in a 100ml measuring flask, the mobile phase was diluted to the scale, and the solution was used as a control solution. According to the high performance liquid chromatography (General 0512) test, using eighteen alkyl silane bonded silica gel as filler; 0.Olmol/L potassium dihydrogen phosphate solution (adjusted to pH 6.2 with 1 mol/L potassium hydroxide solution)-methanol-acetonitrile (85:10 :5) as mobile phase; The detection wavelength was 274nm. The number of theoretical plates shall not be less than 2000 calculated by amrinone peak, and the separation degree between impurity peaks shall meet the requirements. 20ul of the test solution and the control solution were respectively injected into the liquid chromatograph, and the chromatogram was recorded to 5 times of the retention time of the main component peak. If there are impurity peaks in the chromatogram of the test solution, the area of a single impurity peak shall not be greater than 0.5 times (0.5%) of the area of the main peak of the control solution, the sum of each impurity peak area shall not be greater than the main peak area of the control solution (1.0%).
loss on drying
take this product, dry to constant weight at 105°C, weight loss shall not exceed 0.5% (General rule 0831).
ignition residue
take l.Og of this product and check it according to law (General rule 0841). The residue left shall not exceed 0.2%.
Heavy metals
The residue left under the item of taking the ignition residue shall not contain more than 10 parts per million of heavy metal when examined by law (General Principles 0821, Law II).
sterile
take this product, according to the law inspection (General 1101), should comply with the provisions. (For aseptic dispensing)
Last Update：2022-01-01 15:36:48
amrinone - Content determination
Authoritative Data Verified Data
take this product about 0.35g, precision weighing, add hydrochloric acid solution (20-70)70ml, according to the permanent stop titration method (General rule 0701), with sodium nitrite titration solution (0.lmol/L) titration. Each 1 ml of sodium nitrite titration solution (0.1 mol/L) corresponds to 18.72mg of C10H9N30.
Last Update：2022-01-01 15:36:48
amrinone - Category
Authoritative Data Verified Data
cardiotonic drugs.
Last Update：2022-01-01 15:36:48
amrinone - Storage
Authoritative Data Verified Data
light shielding, sealed storage.
Last Update：2022-01-01 15:36:48
amrinone - Amrinone for injection
Authoritative Data Verified Data
This product is amrinone sterile powder or crystal. The amrinone (C10H9N30) content shall be between 90.0% and 110.0% of the label amount.
trait
This product is light yellow to light yellow brown needle-like crystal or crystalline powder.
identification
take this product, according to amrinone under the identification of (1), (2) test, showed the same results.
examination
- acidity: Take 1 bottle of this product, add 1 special solvent for amrinone for injection to dissolve amrinone, dilute it with water to make a solution containing 5mg of amrinone per 1 ml, and determine it according to law (General rule 0631), the pH should be between 3.2 and 4.0.
- clarity of solution take 1 bottle of this product, add 1 vial of amrinone special solvent for injection to dissolve, and the solution should be clear.
- the contents under the item of difference in loading amount of related substances shall be mixed evenly, and an appropriate amount (about 25mg equivalent to amrinone) shall be accurately weighed and placed in a 50ml measuring flask, and 0 shall be added. 1 mol/L hydrochloric acid solution 2ml, ultrasonic dissolution of amrinone, cool, dilute to the scale with mobile phase, shake, as a test solution; Take 1ml of precision measurement, put in a 100ml measuring flask, dilute to the scale with the mobile phase, shake, and serve as a control solution. If there are impurity peaks in the chromatogram of the test solution, the area of a single impurity peak shall not be greater than 0.5 times (0.5%) of the area of the main peak of the control solution, the sum of each impurity peak area shall not be greater than the main peak area of the control solution (1.0%).
- weight loss on drying this product shall be dried at 105°C to constant weight, and the weight loss shall not exceed 0.5% (General rule 0831).
- sterile take this product, with amrinone special solvent for injection after dissolution, by membrane filtration method, inspection according to law (General Principles 1101), should comply with the provisions.
- pyrogen: Take 2 cigarettes of this product, add 1 solvent special for amrinone for injection to dissolve, and add sodium chloride injection to make a solution containing 1142 mg of amrinone per 1 ml, and check according to law (general rule), dose according to the rabbit body weight per lkg slow injection of 5ml, should comply with the provisions.
- others should comply with the relevant provisions under injection (General 0102).
Content determination
take the contents under the difference of loading amount, mix evenly, accurately weigh an appropriate amount (about 25mg of amrinone), put it in a 100ml measuring flask, add 0.1 mol/L hydrochloric acid solution appropriate amount, shake to dissolve and dilute to the scale, shake, take 2ml precision, put 100ml flask, add 0. Dilute the lmol/L hydrochloric acid solution to the scale, shake well, and measure the absorbance at the wavelength of 317nm by UV-Vis spectrophotometry (General rule 0401), add 0. The lmol/L hydrochloric acid solution is made into a solution containing 5ug per lml, and 9 is calculated by the same method.
category
Same as amrinone.
specification
50mg
storage
light shielding, closed storage.
Last Update：2022-01-01 15:36:49
amrinone - Reference Information
| Introduction | amrinone is also known as indanone and is a pyridine phosphodiesterase 3 inhibitor for vaccination. This is a drug that can improve the prognosis of patients with congestive heart failure. Amrinone has been shown to increase heart-induced contractions through high calcium-induced calcium release (CICR). The positive inotropic effect of amrinone is mediated by the selective enhancement of high-gain CICR, which is mediated by cAMP-dependent protein kinase A(PKA) and Ca phosphorylation contributes to the contraction of cardiomyocytes in the 2 calmodulin kinase pathway. |
| biological activity | Amrinone (Inamrinone) is a positive inotropic vasodilator. Amrinone is a selective phosphodiesterase III inhibitor that increases cyclic adenosine monophosphate by preventing the breakdown of cyclic adenosine monophosphate. Amrinone is also an orally active, non-glycoside and non-catecholamine cardiotonic agent. |
| Use | cardiotonic drugs, with enhanced myocardial contractility and direct vasodilation. |
| category | toxic substances |
| toxicity grade | high toxicity |
| Acute toxicity | oral-rat LD50: 102 mg/kg; Oral-mouse LD50: 288 mg/kg |
| flammability hazard characteristics | flammable; Toxic NOx smoke generated by heat |
| storage and transportation characteristics | warehouse ventilation and low temperature drying |
| extinguishing agent | dry powder, foam, sand, carbon dioxide |
Last Update：2024-04-10 22:29:15
Supplier List
Multiple SpecificationsSpot supply
Product Name: Amrinone Visit Supplier Webpage Request for quotationCAS: 60719-84-8
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Multiple SpecificationsSpot supply
Product Name: Amrinone Visit Supplier Webpage Request for quotationCAS: 60719-84-8
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History